60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 ...